GQ1001+pyrotinib
PreclinicalSmall molecule
GQ1001+pyrotinib is one of 17 small molecule programs targeting HER2-positive Breast Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in HER2-Positive Breast Cancer
#DrugCompanyPhaseTrials
1Tukysa
PfizerApproved
Herceptin
RochePhase 3
Perjeta
RochePhase 3
Taxotere
AAvyxa
Phase 3
Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
BL-M07D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
KN026
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
T-DM1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GQ1001+pyrotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFudan University